Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Weidinger, S.; Baurecht, H.; Wagenpfeil, S.; Henderson, J.; Novak, N.; Sandilands, A.; Chen, H.; Rodriguez, E.; ORegan, G.M.; Watson, R.; Liao, H.; Zhao, Y.; Barker, J.N.; Allen, M.; Reynolds, N.; Meggitt, S.; Northstone, K.; Smith, G.D.; Strobl, C.; Stahl, C.; Kneib, T.; Klopp, N.; Bieber, T.; Behren, B.e.h.r.e.n.d.
    Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk (2008), J. Allergy Clin. Immunol., 122, 560-568.
    View publication on PubMed

Application

EC Number Application Comment Organism
3.4.21.117 medicine the KLK7 polymorphism does not confer a risk for eczema Homo sapiens

Protein Variants

EC Number Protein Variants Comment Organism
3.4.21.117 additional information the individual risk of eczema conferred by the SPINK5 polymorphism rs2303067 (Glu420Lys) and a previously described insertion in the 3'-untranslated region of KLK7 and potential epistatic effects between these variants and filaggrin mutations are analysed in patients with eczema and healthy counterparts. No association is seen with the SPINK5 or KLK7 variants. A weaker effect is observed for the SPINK5 variant with maternal transmission in the family-based study Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
3.4.21.117 Homo sapiens
-
-
-

Synonyms

EC Number Synonyms Comment Organism
3.4.21.117 kallikrein 7
-
 Homo sapiens
3.4.21.117 KLK7
-
 Homo sapiens